| scholarly article | Q13442814 |
| review article | Q7318358 |
| P2093 | author name string | David E Clements | |
| Andrew J Bett | |||
| Sangeetha L Sagar | |||
| Beth-Ann G Coller | |||
| Jan H Ter Meulen | |||
| P2860 | cites work | Lethal antibody enhancement of dengue disease in mice is prevented by Fc modification | Q27315772 |
| Synthesis and secretion of recombinant tick-borne encephalitis virus protein E in soluble and particulate form | Q27480299 | ||
| An Immunogenic and Protective Alphavirus Replicon Particle-Based Dengue Vaccine Overcomes Maternal Antibody Interference in Weanling Mice | Q27481478 | ||
| Carboxy-terminally truncated dengue virus envelope glycoproteins expressed on the cell surface and secreted extracellularly exhibit increased immunogenicity in mice | Q27486177 | ||
| A Tetravalent Dengue Vaccine Based on a Complex Adenovirus Vector Provides Significant Protection in Rhesus Monkeys against All Four Serotypes of Dengue Virus | Q27486406 | ||
| Replication-Defective Adenoviral Vaccine Vector for the Induction of Immune Responses to Dengue Virus Type 2 | Q27487570 | ||
| Development of a recombinant tetravalent dengue virus vaccine: Immunogenicity and efficacy studies in mice and monkeys | Q27491049 | ||
| Structure of the dengue virus envelope protein after membrane fusion | Q27643009 | ||
| The envelope glycoprotein from tick-borne encephalitis virus at 2 A resolution | Q27730234 | ||
| Dengue: a continuing global threat | Q28298464 | ||
| Variable surface epitopes in the crystal structure of dengue virus type 3 envelope glycoprotein | Q29618169 | ||
| Conformational changes of the flavivirus E glycoprotein | Q29618170 | ||
| Monoclonal antibody mapping of the envelope glycoprotein of the dengue 2 virus, Jamaica | Q29618177 | ||
| Original antigenic sin and apoptosis in the pathogenesis of dengue hemorrhagic fever | Q29619585 | ||
| Dengue | Q29619772 | ||
| Differing influences of virus burden and immune activation on disease severity in secondary dengue-3 virus infections | Q33342343 | ||
| Comparison of a dengue-2 virus and its candidate vaccine derivative: Sequence relationships with the flaviviruses and other viruses | Q33389831 | ||
| Changing patterns of dengue epidemiology and implications for clinical management and vaccines | Q33498928 | ||
| The growing burden of dengue in Latin America | Q33508340 | ||
| Dengue. | Q34125057 | ||
| Pediatric measles vaccine expressing a dengue tetravalent antigen elicits neutralizing antibodies against all four dengue viruses | Q34129876 | ||
| The perfect mix: recent progress in adjuvant research | Q36844715 | ||
| ISCOMATRIX adjuvant for prophylactic and therapeutic vaccines | Q36968280 | ||
| Understanding the contribution of cellular immunity to dengue disease pathogenesis | Q37287832 | ||
| Replacement of the glycoinositol phospholipid anchor of Drosophila acetylcholinesterase with a transmembrane domain does not alter sorting in neurons and epithelia but results in behavioral defects | Q37380569 | ||
| The human immune response to Dengue virus is dominated by highly cross-reactive antibodies endowed with neutralizing and enhancing activity | Q37448171 | ||
| Markers of dengue disease severity | Q37608067 | ||
| Dengue vaccine candidates in development | Q37608075 | ||
| Strategies for the plant‐based expression of dengue subunit vaccines | Q37812659 | ||
| AS04-adjuvanted human papillomavirus (HPV) types 16 and 18 vaccine (Cervarix®): a review of its use in the prevention of premalignant cervical lesions and cervical cancer causally related to certain oncogenic HPV types | Q37851958 | ||
| Recent clinical experience with vaccines using MPL- and QS-21-containing adjuvant systems | Q37867102 | ||
| Antigenic characterization of flavivirus structural proteins separated by isoelectric focusing | Q39441954 | ||
| Evaluation of Extracellular Subviral Particles of Dengue Virus Type 2 and Japanese Encephalitis Virus Produced bySpodoptera frugiperdaCells for Use as Vaccine and Diagnostic Antigens | Q39674249 | ||
| Recombinant dengue virus-like particles from Pichia pastoris: efficient production and immunological properties | Q39779806 | ||
| A DNA vaccine candidate expressing dengue-3 virus prM and E proteins elicits neutralizing antibodies and protects mice against lethal challenge | Q39918586 | ||
| Phase 2 clinical trial of three formulations of tetravalent live-attenuated dengue vaccine in flavivirus-naïve adults | Q39955421 | ||
| Antibodies determine virulence in dengue | Q40380083 | ||
| A re-evaluation of the mechanisms leading to dengue hemorrhagic fever | Q40380105 | ||
| Immunogenicity and safety of two live-attenuated tetravalent dengue vaccine formulations in healthy Australian adults. | Q40382643 | ||
| Phase I trial of 16 formulations of a tetravalent live-attenuated dengue vaccine | Q40536052 | ||
| Vaccination of human volunteers with monovalent and tetravalent live-attenuated dengue vaccine candidates | Q40541513 | ||
| A dengue-2 Envelope fragment inserted within the structure of the P64k meningococcal protein carrier enables a functional immune response against the virus in mice | Q40544629 | ||
| Enhancing biosynthesis and secretion of premembrane and envelope proteins by the chimeric plasmid of dengue virus type 2 and Japanese encephalitis virus | Q40564204 | ||
| Dengue type 2 virus subviral extracellular particles produced by a stably transfected mammalian cell line and their evaluation for a subunit vaccine | Q40589716 | ||
| Purified dengue 2 virus envelope glycoprotein aggregates produced by baculovirus are immunogenic in mice | Q40622821 | ||
| Immunogenicity of dengue virus type 1 DNA vaccines expressing truncated and full length envelope protein | Q40624173 | ||
| Analysis of a recombinant dengue-2 virus-dengue-3 virus hybrid envelope protein expressed in a secretory baculovirus system | Q40644914 | ||
| Expression of the dengue virus structural proteins in Pichia pastoris leads to the generation of virus-like particles | Q40647664 | ||
| Inoculation of plasmids expressing the dengue-2 envelope gene elicit neutralizing antibodies in mice | Q40652637 | ||
| Mice immunized with a dengue type 2 virus E and NS1 fusion protein made in Escherichia coli are protected against lethal dengue virus infection | Q40680439 | ||
| Analysis of C-terminally truncated dengue 2 and dengue 3 virus envelope glycoproteins: processing in insect cells and immunogenic properties in mice | Q40698875 | ||
| Dengue type-2 virus envelope protein made using recombinant baculovirus protects mice against virus challenge. | Q40703679 | ||
| Recombinant vaccinia viruses co-expressing dengue-1 glycoproteins prM and E induce neutralizing antibodies in mice | Q40706732 | ||
| Use of recombinant fusion proteins and monoclonal antibodies to define linear and discontinuous antigenic sites on the dengue virus envelope glycoprotein | Q40735688 | ||
| Dengue-1 virus envelope glycoprotein gene expressed in recombinant baculovirus elicits virus-neutralizing antibody in mice and protects them from virus challenge | Q40746062 | ||
| Processing, secretion, and immunoreactivity of carboxy terminally truncated dengue-2 virus envelope proteins expressed in insect cells by recombinant baculoviruses | Q40753528 | ||
| The antigenic structure of dengue type 1 virus envelope and NS1 proteins expressed in Escherichia coli | Q40759420 | ||
| Dengue Virus-Specific and Flavivirus Group Determinants Identified with Monoclonal Antibodies by Indirect Immunofluorescence | Q40843891 | ||
| Expression of human dopamine beta-hydroxylase in Drosophila Schneider 2 cells | Q41256199 | ||
| Regulated expression allows high level production and secretion of HIV-1 gp120 envelope glycoprotein in Drosophila Schneider cells | Q41698821 | ||
| ISCOMATRIX() vaccines: Safety in human clinical studies. | Q51905178 | ||
| Cell lines derived from late embryonic stages of Drosophila melanogaster | Q52834135 | ||
| P433 | issue | 42 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Dengue virus | Q476209 |
| P304 | page(s) | 7267-7275 | |
| P577 | publication date | 2011-07-21 | |
| P1433 | published in | Vaccine | Q7907941 |
| P1476 | title | The development of recombinant subunit envelope-based vaccines to protect against dengue virus induced disease | |
| P478 | volume | 29 |
| Q59245616 | A Recombinant Subunit Based Zika Virus Vaccine Is Efficacious in Non-human Primates |
| Q27116692 | A Tetravalent Sub-unit Dengue Vaccine Formulated with Ionizable Cationic Lipid Nanoparticle induces Significant Immune Responses in Rodents and Non-Human Primates |
| Q36849774 | A dengue DNA vaccine formulated with Vaxfectin® is well tolerated, and elicits strong neutralizing antibody responses to all four dengue serotypes in New Zealand white rabbits |
| Q38944133 | A novel lipid nanoparticle adjuvant significantly enhances B cell and T cell responses to sub-unit vaccine antigens |
| Q38738484 | A recombinant live attenuated tetravalent vaccine for the prevention of dengue |
| Q38658737 | A recombinant, chimeric tetravalent dengue vaccine candidate based on a dengue virus serotype 2 backbone |
| Q38184218 | A review of successful flavivirus vaccines and the problems with those flaviviruses for which vaccines are not yet available |
| Q41928846 | An Envelope-Modified Tetravalent Dengue Virus-Like-Particle Vaccine Has Implications for Flavivirus Vaccine Design |
| Q36667964 | An alphavirus vector-based tetravalent dengue vaccine induces a rapid and protective immune response in macaques that differs qualitatively from immunity induced by live virus infection |
| Q37069430 | An engineered mutant of HIV-1 gp120 formulated with adjuvant Quil A promotes elicitation of antibody responses overlapping the CD4-binding site |
| Q38158670 | An update on Zika vaccine developments |
| Q38121757 | Challenges for the formulation of a universal vaccine against dengue. |
| Q38140035 | Challenges in reducing dengue burden; diagnostics, control measures and vaccines |
| Q28114506 | Characterization of cytopathic factors through genome-wide analysis of the Zika viral proteins in fission yeast |
| Q33784307 | Characterization of the ectodomain of the envelope protein of dengue virus type 4: expression, membrane association, secretion and particle formation in the absence of precursor membrane protein |
| Q40198225 | Construction of recombinant Kluyveromyces marxianus UFV-3 to express dengue virus type 1 nonstructural protein 1 (NS1). |
| Q33408300 | Current progress in dengue vaccines |
| Q37694852 | DENV-2 subunit proteins fused to CR2 receptor-binding domain (P28)-induces specific and neutralizing antibodies to the Dengue virus in mice. |
| Q27304342 | Dengue E Protein Domain III-Based DNA Immunisation Induces Strong Antibody Responses to All Four Viral Serotypes |
| Q42996339 | Dengue infection. |
| Q34367194 | Dengue vaccines: recent developments, ongoing challenges and current candidates |
| Q38960985 | Dengue vaccines: what we know, what has been done, but what does the future hold? |
| Q37694855 | Dengue virus photo-inactivated in presence of 1,5-iodonaphthylazide (INA) or AMT, a psoralen compound (4'-aminomethyl-trioxsalen) is highly immunogenic in mice |
| Q58112353 | Dengue-2 virus-like particle (VLP) based vaccine elicits the highest titers of neutralizing antibodies when produced at reduced temperature |
| Q59352698 | Dengue: a growing threat requiring vaccine development for disease prevention |
| Q40715749 | Design and Purification of Subunit Vaccines for Prevention of Clostridium difficile Infection |
| Q38201151 | Developing a dengue vaccine: progress and future challenges |
| Q40140795 | Development of a capillary zone electrophoresis method for dose determination in a tetravalent dengue vaccine candidate |
| Q30236000 | Disease and economic burdens of dengue |
| Q41922147 | Elaboration of tetravalent antibody responses against dengue viruses using a subunit vaccine comprised of a single consensus dengue envelope sequence |
| Q36363996 | Enhanced performance of an innovative dengue IgG/IgM rapid diagnostic test using an anti-dengue EDI monoclonal antibody and dengue virus antigen |
| Q39611325 | Expression of enhancing-activity-free neutralizing antibody against dengue type 1 virus in plasmid-inoculated mice |
| Q38721146 | Generation and characterization of a monoclonal antibody against duck Tembusu virus envelope protein |
| Q35982791 | Identification of human neutralizing antibodies that bind to complex epitopes on dengue virions |
| Q38125045 | Identifying protective dengue vaccines: guide to mastering an empirical process |
| Q40037937 | Immunization with truncated envelope protein of Zika virus induces protective immune response in mice |
| Q35548048 | Immunogenicity and efficacy of flagellin-envelope fusion dengue vaccines in mice and monkeys |
| Q33867337 | In Vitro Assembly and Stabilization of Dengue and Zika Virus Envelope Protein Homo-Dimers |
| Q38978415 | Inhibition of dengue virus replication by diisopropyl chrysin-7-yl phosphate |
| Q36616521 | Lower IgG somatic hypermutation rates during acute dengue virus infection is compatible with a germinal center-independent B cell response. |
| Q37736723 | Multi-walled carbon nanotubes functionalized with recombinant Dengue virus 3 envelope proteins induce significant and specific immune responses in mice |
| Q58699988 | Nanoparticle delivery of a tetravalent E protein subunit vaccine induces balanced, type-specific neutralizing antibodies to each dengue virus serotype |
| Q37721304 | Neutralizing Antibody Response and Efficacy of Novel Recombinant Tetravalent Dengue DNA Vaccine Comprising Envelope Domain III in Mice |
| Q38596321 | Next generation dengue vaccines: A review of the preclinical development pipeline |
| Q54231305 | Physiological temperatures reduce dimerization of dengue and Zika virus recombinant envelope proteins. |
| Q66679798 | Potent neutralizing antibodies elicited by dengue vaccine in rhesus macaque target diverse epitopes |
| Q39025905 | Potential for treatment and a Zika virus vaccine |
| Q27493140 | Precisely Molded Nanoparticle Displaying DENV-E Proteins Induces Robust Serotype-Specific Neutralizing Antibody Responses |
| Q38605198 | Preclinical and clinical development of a dengue recombinant subunit vaccine |
| Q40148624 | Preclinical development of a dengue tetravalent recombinant subunit vaccine: Immunogenicity and protective efficacy in nonhuman primates |
| Q26314423 | Prospects for dengue vaccines for travelers |
| Q26700070 | Rapid isolation of dengue-neutralizing antibodies from single cell-sorted human antigen-specific memory B-cell cultures |
| Q26766156 | Recent advances in understanding dengue |
| Q38303232 | Recent progress in dengue vaccine development |
| Q47550067 | Recombinant Zika Virus Subunits Are Immunogenic and Efficacious in Mice |
| Q50438438 | Recombinant interleukin 6 with M cell-targeting moiety produced in Lactococcus lactis IL1403 as a potent mucosal adjuvant for peroral immunization |
| Q39028302 | Recombinant lipidated dengue-4 envelope protein domain III elicits protective immunity |
| Q36026210 | Safety and Immunogenicity of a Dengue Virus Serotype-1 Purified-Inactivated Vaccine: Results of a Phase 1 Clinical Trial |
| Q42733080 | Scientific challenges and opportunities in developing novel vaccines for the emerging and developing markets: New Technologies in Emerging Markets, October 16th-18th 2012, World Vaccine Congress, Lyon |
| Q39470840 | Secretion of dengue virus envelope protein ectodomain from mammalian cells is dependent on domain II serotype and affects the immune response upon DNA vaccination |
| Q38773323 | Status of vaccine research and development of vaccines for dengue |
| Q36029040 | Synthetic B-Cell Epitopes Eliciting Cross-Neutralizing Antibodies: Strategies for Future Dengue Vaccine |
| Q37611829 | Targeting host factors to treat West Nile and dengue viral infections |
| Q40254340 | Targeting of envelope domain III protein of DENV type 2 to DEC-205 receptor elicits neutralizing antibodies in mice |
| Q35594746 | The burden of dengue and chikungunya worldwide: implications for the southern United States and California |
| Q35737990 | The contribution of non-human primate models to the development of human vaccines |
| Q26314683 | The dengue vaccine pipeline: Implications for the future of dengue control |
| Q38540058 | Trials and tribulations on the path to developing a dengue vaccine |
| Q28077521 | Vaccines and immunization strategies for dengue prevention |
| Q39172722 | Vaccines licensed and in clinical trials for the prevention of dengue |
| Q38554795 | Viral vaccines and their manufacturing cell substrates: New trends and designs in modern vaccinology |
| Q34630584 | Will dengue vaccines be used in the public sector and if so, how? Findings from an 8-country survey of policymakers and opinion leaders |
Search more.